MediVet-America Partners With Butler Schein Animal Health to Distribute World's Leading Animal Stem Cell Technology to …

Global leader in animal stem cell technology is poised for significant expansion through new partnership with top U.S. companion animal health distribution company Continue reading

Posted in Stem Cell Therapy | Tagged , , , , , , , , , , , | Comments Off

Promising new compound for treating stroke produced

Washington, Feb 22 (ANI): A new chemical compound that has great potential for the possible treatment of brain damage caused by stroke has been designed and produced by researchers at the University of Copenhagen. The compound binds 1,000 times more effectively to the target protein in the brain than the potential drug currently being tested on stroke victims. Stroke causes the brain to release large amounts of glutamate, an activating signal compound, all at once Continue reading

Posted in Stroke Treatment | Tagged , , , , , , , , , , , , , , | Comments Off

Amarantus BioSciences Presents Data on MANF at the 14th Annual Meeting of the American Society of Experimental …

SUNNYVALE, CA–(Marketwire -02/22/12)- Amarantus BioSciences, Inc. (OTC.BB: AMBS.OB – News), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein being developed for the treatment of Parkinson's Disease, will present preclinical data on MANF at the 14th Annual Meeting of the American Society of Experimental Neurotherapeutics (ASENT) Conference at the Ritz Carlton Hotel in Washington, D.C. during the Pipeline session on Friday, February 24th, 2012 at 2:15pm ET. Continue reading

Posted in Parkinson's Treatment | Tagged , , , , , , , , , , | Comments Off

Monkeys' Parkinson's woes eased via stem cells

Thursday, Feb. 23, 2012 KYOTO — Researchers have succeeded in improving the treatment of Parkinson's disease by using human embryonic stem cells to create nerve cells that produce dopamine and then transplanting the cells into monkeys' brains. Continue reading

Posted in Parkinson's Treatment | Tagged , , , , , , , , , , , , , , | Comments Off

Traumatic Brain Injury – Clazosentan May Block Harmful Effects

Editor's Choice Main Category: Neurology / Neuroscience Article Date: 22 Feb 2012 – 5:00 PST email to a friend   printer friendly   opinions   Current Article Ratings: Patient / Public: Healthcare Prof: A study in rats has found that a new medication called clazosentan, may be effective in blocking the harmful effects of traumatic brain injury (TBI). The study will be presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012. Michael Kaufman, study author, a second year medical student at Wayne State University School of Medicine in Detroit, and member of the American Academy of Neurology, explained: “There are currently no primary treatments for TBI, so this research provides hope that effective treatments can be developed.” Christian Kreipke, MD, also with Wayne State University School of Medicine, is lead researcher on the study Continue reading

Posted in Brain Injury Treatment | Tagged , , , , , , , , , , , , , | Comments Off

A new link between traumatic brain injury and post-traumatic stress disorder

Public release date: 22-Feb-2012 [ | E-mail | Share ] Contact: Rhiannon Bugno Biol.Psych@utsouthwestern.edu 214-648-0880 Elsevier Philadelphia, PA, February 22, 2012 ? Mild traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) are cardinal injuries associated with combat stress, and TBI increases the risk of PTSD development. Continue reading

Posted in Brain Injury Treatment | Tagged , , , , , , , , , , , | Comments Off

MS centre moves into new facility

Report by Samantha Pope Wednesday, February 22, 2012 1:00 PM A MULTIPLE Sclerosis charity which started in Nailsea more than 25 years ago has moved to a new facility in Bradley Stoke. Continue reading

Posted in MS Treatment | Tagged , , , , , , , , , | Comments Off

D-Pharm mulls buying Thrombotech

Thrombotech's peptide, THR-18 for the treatment of thrombolytic strokes, is undergoing a Phase IIa clinical safety and efficacy trial. Continue reading

Posted in ALS Treatment | Tagged , , , , , , | Comments Off

Repligen Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended December 31, 2011

WALTHAM, Mass.–(BUSINESS WIRE)– Repligen Corporation (NASDAQ:RGEN – News) today reported preliminary financial results for the quarter and nine-month fiscal period ended December 31, 2011. These results reflect significant accomplishments of the Company during the period, highlighted by the completion of our acquisition of Novozymes Biopharma Sweden AB on December 20, 2011 and the successful filing of the Company’s first new drug application (NDA) for SecreFlo™ on December 21, 2011. Continue reading

Posted in Ataxia Treatment | Tagged , , , , , , , , , , , , | Comments Off

Panasonic Announces Relationship With AAG Health & Wellness Featuring the CardioHealth® Station

SECAUCUS, N.J. and MIAMI, Feb Continue reading

Posted in Hormone Replacement Therapy | Tagged , , , , , , , , , , , , , , | Comments Off